Latest Intelligence on Immunology and Inflammation in South and Central America

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
Expert View
Expert View

World Congress on Osteoporosis highlights changing face of bone health

Datamonitor attended this year's International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, the most important meeting on the osteoporosis calendar. A number of major pharmaceutical firms had a presence at the meeting, indicating the significance of this market.

Published By Datamonitor
18 May 2010
ResearchWire
ResearchWire

Vaccines: sales show global growth

Published By Datamonitor
17 Mar 2006
ResearchWire
ResearchWire

Upper GI disorders: prevalence in the seven major markets

Published By Datamonitor
10 Aug 2007
ResearchWire
ResearchWire

Transplantation: Astellas takes the lead

Published By Datamonitor
18 May 2006
CommentWire
CommentWire

Servier: new Protelos data highlight shifting focus in osteoporosis research

As one of the lead sponsors of this year's World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, Servier presented new data for its dual action drug Protelos. Discussion of the therapy led on to the importance of companies using bone quality assessment, rather than relying on measurements of bone mineral density.

Published By Datamonitor
18 May 2010
CommentWire
CommentWire

Roche: new MabThera data challenges anti-TNFs

New data from Roche's IMAGE study presented at the European League Against Rheumatism congress show that administering MabThera at first-line may significantly slow joint damage and improve clinical outcomes in patients with rheumatoid arthritis. However, Datamonitor does not predict that these data will change the current treatment paradigms, as touted by the investigators.

Published By Datamonitor
12 Jun 2009
CommentWire
CommentWire

Roche: implementing cuts to maintain its strong fiscal position

In light of R&D setbacks and slowing sales growth, Roche has outlined a number of cost-saving initiatives, including the termination of 4,800 jobs. Despite a challenging year, Roche's above-average operating profit in 2009 is expected to be maintained, and these new initiatives are expected to result in cost savings of up to $2.4bn per year, leaving the company in a strong financial position.

Published By Datamonitor
17 Nov 2010
ResearchWire
ResearchWire

Rheumatoid arthritis: research points to genetic component

Published By Datamonitor
28 Jun 2007
ResearchWire
ResearchWire

Psoriasis market: Humira set to overtake Enbrel

Published By Datamonitor
22 Jan 2007
CommentWire
CommentWire

Pfizer: stacking up positive data for new rheumatoid arthritis drug

Positive results from a second Phase III trial take Pfizer's tofacitinib one step closer to becoming the first novel oral small molecule for the treatment of rheumatoid arthritis. While these data contribute to tofacitinib's clinical and commercial offering, pricing and product positioning remains a concern. Nonetheless Datamonitor views tofacitinib as a future blockbuster in rheumatoid arthritis.

Published By Datamonitor
07 Mar 2011

« | 1 | 2 | 3 | 4 | » »|

No help is available.